FR15C0033I1 - - Google Patents

Info

Publication number
FR15C0033I1
FR15C0033I1 FR15C0033C FR15C0033I1 FR 15C0033 I1 FR15C0033 I1 FR 15C0033I1 FR 15C0033 C FR15C0033 C FR 15C0033C FR 15C0033 I1 FR15C0033 I1 FR 15C0033I1
Authority
FR
France
Prior art keywords
leashes
new
chelators
conjugation
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR15C0033I1 publication Critical patent/FR15C0033I1/fr
Application granted granted Critical
Publication of FR15C0033I2 publication Critical patent/FR15C0033I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/50—Clinical applications
    • A61B6/508—Clinical applications for non-human patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules

Abstract

New macromolecular carriers for drugs and diagnostic agents are described that make use of the chemical attachment of new leashes to oligomeric backbone structures. The synthesis of these leashes and their facile creation, reaction and conjugation with chelators and ligands makes them ideal candidates for use in medicine, and especially diagnostics.
FR15C0033C 1999-05-14 2015-04-23 MACROMOLECULAR SUPPORT BASED ON DEXTRAN FOR THE ADMINISTRATION OF A DIAGNOSTIC OR THERAPEUTIC AGENT Active FR15C0033I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13432999P 1999-05-14 1999-05-14
PCT/US2000/013300 WO2000069473A2 (en) 1999-05-14 2000-05-12 Macromolecular carrier for drug and diagnostic agent delivery

Publications (2)

Publication Number Publication Date
FR15C0033I1 true FR15C0033I1 (en) 2015-06-26
FR15C0033I2 FR15C0033I2 (en) 2016-09-09

Family

ID=22462862

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0033C Active FR15C0033I2 (en) 1999-05-14 2015-04-23 MACROMOLECULAR SUPPORT BASED ON DEXTRAN FOR THE ADMINISTRATION OF A DIAGNOSTIC OR THERAPEUTIC AGENT

Country Status (10)

Country Link
US (1) US6409990B1 (en)
EP (1) EP1178838B1 (en)
JP (2) JP4056701B2 (en)
AT (1) ATE277642T1 (en)
AU (1) AU5270500A (en)
DE (1) DE60014359T2 (en)
ES (1) ES2228536T3 (en)
FR (1) FR15C0033I2 (en)
NL (1) NL300736I1 (en)
WO (1) WO2000069473A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
JP4163381B2 (en) 1997-11-17 2008-10-08 カリフォルニア・インスティテュート・オブ・テクノロジー Magnetic resonance contrast agents for the detection of physiological agents
DE60014359T2 (en) * 1999-05-14 2006-02-23 The Regents Of The University Of California, Oakland MACROMOLECULAR CARRIER BASED ON DEXTRAN FOR MEDICINAL PRODUCTS AND DIAGNOSTICUM DISTRIBUTION
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US6906182B2 (en) 2000-12-01 2005-06-14 Cell Works Therapeutics, Inc. Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
WO2003057715A2 (en) * 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
WO2004070012A2 (en) * 2003-02-03 2004-08-19 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
WO2005117995A1 (en) * 2004-06-03 2005-12-15 Joji Kitayama Application of hyaluronic acid to sentinel lymph node identification
US7381400B2 (en) * 2004-07-13 2008-06-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Injection of a radioactive dye for sentinel lymph node identification
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
DE102005018330B4 (en) 2005-04-20 2007-04-19 Siemens Ag System for generating CT image data records and for irradiating a tumor patient
JP4934802B2 (en) * 2005-05-30 2012-05-23 国立大学法人信州大学 Lymphoid cell adhesion substance, lymphatic drug transport material and drug containing the same
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
CA2660717A1 (en) * 2006-08-17 2008-02-21 Epix Pharmaceuticals, Inc. Methods for lymph system imaging
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US11077212B2 (en) 2010-08-24 2021-08-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
ES2682345T3 (en) 2012-09-27 2018-09-20 Biocare Medical, Llc Antiuroplachin II antibody systems and procedures
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (en) 2013-02-28 2019-07-01 Biocare Medical Llc Systems and Methods with Anti-p40 Antibodies
JP6163698B2 (en) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 Novel polysaccharide metal complex compound recognizing macrophage mannose receptor and pharmaceutical composition thereof
CN105764529A (en) * 2013-07-22 2016-07-13 纳维迪亚生物制药有限公司 Compositions, methods and kits for diagnosing and treating CD206 expressing cell-related disorders
CN104511030A (en) * 2013-09-29 2015-04-15 复旦大学 Dual-modal nano imaging drug Dex-Rho-99mTc based on glucan
EP3052522B1 (en) 2013-10-03 2019-12-11 Biocare Medical, LLC Anti-sox10 antibody systems and methods
DK3154587T3 (en) 2014-06-13 2020-03-09 Tenboron Oy CONJUGATES INCLUDING AN ANTI-EGFR1 ANTIBODY
CA2955441C (en) * 2014-07-17 2023-03-14 Ohio State Innovation Foundation Dextran conjugates for targeting macrophages and other cd296-expressing cells
WO2016011415A2 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
CA2974634A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
CN106317237B (en) * 2015-07-03 2019-07-19 华中科技大学 A kind of Radix Angelicae Sinensis polysaccharide derivative and its synthetic method for SPECT imaging
CN108348619A (en) 2015-09-25 2018-07-31 瑟日尼有限责任公司 The dextran amine of the mannose coupling of SN-117M labels
US20190076557A1 (en) 2015-10-05 2019-03-14 Serene, Llc Hyaluronan sn-117m colloid for radiosynoviorthesis and symptomatic therapy related applications
CA3039519A1 (en) * 2016-10-04 2018-04-12 Cardinal Health 414, Llc Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
IL265846B2 (en) * 2016-10-07 2024-02-01 Navidea Biopharmaceuticals Inc Compounds and methods for diagnosis and treatment of viral infections
JP6329302B2 (en) * 2017-05-10 2018-05-23 国立大学法人千葉大学 Novel polysaccharide metal complex compound recognizing macrophage mannose receptor and pharmaceutical composition thereof
JP2022544836A (en) * 2019-08-19 2022-10-21 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド Compositions and Related Methods for Depleting M2 Macrophages and Myeloid-Derived Suppressor Cells
US20210145989A1 (en) * 2019-09-30 2021-05-20 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
US11497763B1 (en) 2020-07-01 2022-11-15 Physis International LLC Compounds and methods for treating and diagnosing RNA virus infections
WO2022011184A1 (en) * 2020-07-08 2022-01-13 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
US11833170B2 (en) * 2022-02-04 2023-12-05 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286598C (en)
US5175269A (en) * 1984-01-30 1992-12-29 Enzo Diagnostics, Inc. Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group
US4707440A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Nucleic acid hybridization assay and detectable molecules useful in such assay
SE465907B (en) * 1984-11-01 1991-11-18 Nyegaard & Co As DIAGNOSTIC AGENT CONTENT AND PARAMAGNETIC METAL
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
CS263561B1 (en) * 1987-09-18 1989-04-14 Kery Vladimir Process for preparing water soluble allylderivatives of oligo and polysaccharides
DD286598A5 (en) * 1989-06-29 1991-01-31 Adw Der Ddr,Zi F. Mulekularbiologie,De PROCESS FOR THE INTRODUCTION OF PRIMARY AMINO GROUPS IN WATER-SOLUBLE POLYMERS
US5789578A (en) 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
WO1998018497A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO1998023293A1 (en) 1996-11-28 1998-06-04 Nihon Schering K.K. Contrast compound, contrast medium for mri, and method for mri
DE60014359T2 (en) * 1999-05-14 2006-02-23 The Regents Of The University Of California, Oakland MACROMOLECULAR CARRIER BASED ON DEXTRAN FOR MEDICINAL PRODUCTS AND DIAGNOSTICUM DISTRIBUTION

Also Published As

Publication number Publication date
ATE277642T1 (en) 2004-10-15
AU5270500A (en) 2000-12-05
DE60014359T2 (en) 2006-02-23
JP2007332380A (en) 2007-12-27
NL300736I2 (en) 2016-01-26
DE60014359D1 (en) 2004-11-04
JP2002544243A (en) 2002-12-24
EP1178838B1 (en) 2004-09-29
US6409990B1 (en) 2002-06-25
NL300736I1 (en) 2016-01-26
WO2000069473A2 (en) 2000-11-23
ES2228536T3 (en) 2005-04-16
FR15C0033I2 (en) 2016-09-09
EP1178838A2 (en) 2002-02-13
JP4056701B2 (en) 2008-03-05
WO2000069473A3 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
NL300736I2 (en)
TR199901361T2 (en) Sulfonamide derivatives, preparation process and their use as medicine
ES2179490T3 (en) DERIVATIVES OF 1,2,4-TRIAZOLO (3,4-A) FTALAZINA SUBSTITUTED AS LIGANDOS DE GABA ALFA 5.
TR200103525T2 (en) Bicyclic polyaminocyte metal complexes, method for preparing them and their use in medical imaging.
TR200001544T2 (en) New compounds.
NO20021701L (en) Process for the preparation of a conjugate of polyglutamate and a therapeutic agent
NO20014415L (en) Medical preparations for the treatment of <alfa> -galactosidase A deficiency
GB9818916D0 (en) Use
TR200200226T2 (en) Carbonacitamides, the drug containing these compounds, their use and production.
IL146125A0 (en) Novel quinones as disease therapies
HK1068251A1 (en) Aminoderivatives of biotin and their conjugates with macrocyclic chelating agents
YU68702A (en) Novel lhrh-antagonists, production and use thereof as medicament
EP1667716A4 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
DE3382137D1 (en) DNA SEQUENCE ENCODING FOR THE DR BETA CHAIN LOCUS OF THE HUMAN LYMPHOCYTANTIGEN COMPLEX AND POLYPEPTIDES, DIAGNOSTIC TYPING METHODS AND PRODUCTS RELATING TO THIS.
IS2597B (en) Medicines composed of R, R-formoterol and cyclesonide
TR200503846T2 (en) Alternative use for modified release insulin sensitiser and use
AU2003255395A8 (en) Novel nickel-carbene, palladium-carbene and platinum-carbene complexes, their production and use in catalytic reactions
EP1223217A4 (en) Transporter genes oatp-b, c, d and e
CA2199145A1 (en) Novel n3s2 chelating ligands optionally radiolabelled with tc or re, useful for diagnostic or therapeutic applications
FR2789588B1 (en) USE OF AN OMPA ENTEROBACTERIA PROTEIN ASSOCIATED WITH AN ANTIGEN IN A PHARMACEUTICAL COMPOSITION FOR GENERATING OR INCREASING ANTIVIRAL, PEST CONTROL OR ANTITUMOR CYTOTOXIC RESPONSE
EA200000163A1 (en) ANTI-TUMOR MEDICINE
ATE222103T1 (en) INCLUSION COMPLEXES IN AQUEOUS SOLUTION
TR199800904T2 (en) Production of new quinoxalindione derivatives and their use in medicines
DE3878988D1 (en) 1,2-DI (4-ISOBUTYLPHENYL) AETHYLENE, THE PRODUCTION AND USE THEREOF AS AN INTERMEDIATE PRODUCT.
PT980379E (en) CHEMICAL OLIGONUCLEOTIDES AND THEIR USE